Exelixis EXEL Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's total equity?
- Exelixis (EXEL) reported total equity of $1.94B in Q1 2026.
- How has Exelixis's total equity changed year-over-year?
- Exelixis's total equity decreased by 9.2% year-over-year, from $2.13B to $1.94B.
- What is the long-term trend for Exelixis's total equity?
- Over 5 years (2020 to 2025), Exelixis's total equity has grown at a 2.8% compound annual growth rate (CAGR), from $1.88B to $2.16B.
- What does total equity mean?
- The total value of the company that belongs to the shareholders after all debts are paid.
- How do you interpret total equity?
- An increase indicates growth in net assets, while a consistent decrease may signal financial distress or aggressive share buybacks.
- How does total equity compare across companies?
- Used as a baseline for valuation metrics like Price-to-Book ratio across the pharmaceutical industry.